Evolus, Inc. (NASDAQ:EOLS) Receives $16.00 Consensus Price Target from Analysts

Evolus, Inc. (NASDAQ:EOLS) has earned an average rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.00.

Several brokerages recently issued reports on EOLS. BTIG Research reaffirmed a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th.

Evolus Price Performance

EOLS stock traded down $0.24 during trading on Friday, hitting $6.61. The stock had a trading volume of 639,122 shares, compared to its average volume of 721,332. Evolus has a twelve month low of $3.86 and a twelve month high of $10.20. The company’s 50-day moving average price is $6.59 and its two-hundred day moving average price is $5.55. The stock has a market capitalization of $435.30 million, a P/E ratio of -9.87 and a beta of 1.32.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. As a group, sell-side analysts expect that Evolus will post -0.38 EPS for the current fiscal year.

Institutional Trading of Evolus

Large investors have recently modified their holdings of the stock. Larson Financial Group LLC grew its stake in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Evolus in the fourth quarter valued at $34,000. Wexford Capital LP acquired a new stake in shares of Evolus in the 3rd quarter valued at about $37,000. Tower Research Capital LLC TRC grew its position in Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after purchasing an additional 5,691 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Evolus during the 3rd quarter worth approximately $48,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.